Weight Watchers (NASDAQ:WW) reported that it will begin offering Foundayo (orforglipron), Eli Lilly and Company’s newly FDA-approved oral GLP-1 medication, through its Med+ platform, prompting a 17% rise in the company’s shares on Thursday.
The company said Foundayo will provide Med+ members an alternative to injectable therapies - a once-daily, oral option for adults with obesity or who are overweight with weight-related medical problems. Access to the medication will be coordinated through Weight Watchers’ affiliated medical groups and paired with care from board-certified clinicians, insurance assistance, and supplemental tools intended to support treatment adherence and outcomes.
For members who opt to pay out of pocket, Weight Watchers indicated that pricing for the lowest dose will start at $149 per month, with higher doses carrying different price points. In addition to medication access, all Med+ participants will receive direct entry to the Weight Watchers GLP-1 Success program, which is intended to offer guidance before, during, and after medication use.
Weight Watchers cited internal program data showing that among Med+ members prescribed a GLP-1 who regularly engaged with the GLP-1 Success Program for 12 months, participants achieved on average 29.1% greater body-weight loss compared with those who did not engage in behavioral support.
The company described the inclusion of Foundayo as an enlargement of its portfolio of FDA-approved oral GLP-1 therapies provided within a clinically supported framework. Through Med+, clinically eligible members will be able to access the newly approved medication alongside the company’s existing treatment options.
This announcement is part of Weight Watchers’ ongoing effort to position its Med+ offering within the changing weight-health landscape by coupling FDA-approved pharmacologic options with an integrated support model of clinicians, insurance navigation, and behavior-focused programs.
No additional financial projections, timeline for rollout beyond the availability statement, or enrollment estimates were provided in the company’s announcement.